Opioid risk mitigation, naloxone and tapering

Long-term opioid therapy is managed for safety, not stopped by reflex. Offer naloxone at 50 MME/day or with added risk, avoid sedative stacking, confirm unexpected urine results, and taper slowly and collaboratively.

1. Calculate total daily MME from all sources. CDC 2022 conversion factors are 1.5 for oxycodone (mg/day) and 2.4 for transdermal fentanyl (mcg/h); they are estimates and should not be used to convert directly between opioids ¹.
2. At 50 MME/day, add precautions and naloxone. CDC advises more frequent follow-up and offering naloxone with overdose education to patients and household members at or above 50 MME/day, or when other risk factors are present ¹. Naloxone 4 mg nasal spray has been sold over the counter since 2023 ².
3. Avoid stacking CNS depressants. Opioids with benzodiazepines raise the risk of fatal respiratory depression; CDC advises caution, PDMP review, coordination and naloxone rather than reflexive discontinuation ¹. Gabapentinoid labels warn of respiratory depression with opioids ³, and FDA 2025 opioid labeling adds gabapentinoids to its CNS-depressant interaction warnings ⁶.
4. Interpret urine drug tests carefully. Opiate immunoassays detect morphine and do not reliably detect oxycodone or fentanyl; confirm with a specific method before acting, and do not dismiss patients over a result ¹.
5. Taper slowly after long-term use. After a year or more, tapers of 10% per month or slower are better tolerated; 10% per week suits only shorter courses. Rapid tapers and abrupt stops risk withdrawal, overdose and mental health crises ¹.
6. Treat emerging opioid use disorder. CDC recommends offering or arranging medication for opioid use disorder; detoxification alone raises the risk of return to use and overdose ¹.

Depression or suicidal ideation in a patient on long-term opioids: give naloxone, counsel on lethal means, treat the depression, and avoid abrupt tapering, which is linked to suicide risk ¹⁴.

• The 50 MME/day threshold triggers naloxone and closer follow-up under CDC 2022 ¹.
• Opioid plus benzodiazepine: caution and coordination, not automatic discontinuation of either drug ¹.
• For anxiety in a patient on opioids, CDC favors CBT or nonbenzodiazepine medications ¹.
• A negative opiate immunoassay can be a false negative for oxycodone; confirm by a specific assay ¹.
• Tapers after at least a year of opioids: 10% per month or slower, individualized, with pauses allowed ¹.
• In adults 65 and older, Beers advises avoiding combinations of three or more CNS-active drugs ⁵.
• OTC naloxone nasal spray (4 mg) was approved by the FDA in March 2023 ².
• FDA 2025 class-wide opioid labeling: harm rises with dose and persists throughout therapy; opioid-induced esophageal dysfunction is a new GI warning ⁶.

• Stopping opioids abruptly when a benzodiazepine is discovered; CDC advises caution and coordination instead ¹.
• Treating a negative opiates screen as proof of nonadherence to oxycodone ¹.
• Using a weekly 10% taper for someone on opioids for years ¹.
• Treating ER/LA opioids as routine; FDA 2025 labeling reserves them for when alternatives, including IR opioids, are inadequate ⁶.